AstraZeneta's revenue in China up 35% year-on-year in 2019

February 14th AstraZene reported 2019 revenues of $4.880bn in China, up 35 per cent year-on-year and accounting for 20.7 per cent of AstraZeneta's global revenue. Revenue rose 25 percent to $1.19 billion in the fourth quarter.shows that the Chinese market is one of AstraZeneta's main contributors to future revenue growth. But when it comes to its 2020 sales targets for China, Marc Dunoyer, AstraZenecom's chief financial officer, said AstraZene cum's business was expected to be adversely affected for months by the new coronavirus outbreak. And this adverse effect is not just happening in China, it is likely to affect the world. We will closely monitor the development of the disease and will release an update in our results for the first quarter of 2020.Before that, three large multinational drug companies, Mercedon, Sanofi and Noor and Nord, expressed similar concerns to investors, noting that not only were Chinese employees required to live in isolation and work against each other, but that hospitals had focused on treating patients with neo-crown pneumonia and that attention to treating chronic conditions such as diabetes had declined.despite the impact of the outbreak, AstraZeneta's chief executive, Pascal Soriot, said AstraZeneta's sales would continue to rise in 2020, with growth expected to be between "high single digits and lower double-digit percentages".last year, AstraZeneta has weathered the patent cliff crisis of several heavyweight products and embarked on a new path of recovery and growth. Among them, pd-l1 monoantimmune imfinzi (dvaliyu monoanti) for cancer immunotherapy, three generations of egfr inhibitor tagrisso (Ohithini) for targeted treatment of lung cancer, and parp inhibitor lynparza (Olapali) for ovarian and breast cancer, providing a "strong heart" for its steady growth in global sales.addition, AstraZeneta has two other drugs that will be fully available this year to boost its performance, including: 1) btk inhibitor calquence, which was approved by fda in November 2019 for the treatment of chronic lymphocytic leukemia in adults (cll) and small lymphocytic lymphoma (sll), which contributed sales of $56 million in the month to market; 2) antibody conceding drug enhertu, which was approved by fda at the end of December 2019 for the treatment of her2-positive breast cancer. Most analysts are in agreement with their "heavy bomb" outlook, which is expected to peak at more than $4.5 billion a year.For AstraZeneta's business in The Chinese market in 2020, Pascal Soriot said: the new coronavirus transmission methods and travel restrictions or uncertainties affecting its ability to sell in China, but 2020 is still another year of steady growth for AstraZeneta, its drug sales capacity will become more balanced in parts of China or the market as a whole. (Medical Rubik's Cube)